Opsens Dirección

Dirección controles de criterios 3/4

El CEO de Opsens es Louis Laflamme , nombrado en Jan 2013, tiene una permanencia de 10.92 años. compensación anual total es CA$425.37K, compuesta por 76.9% salario y 23.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.59% de las acciones de la empresa, por valor de CA$1.98M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 9.9 años, respectivamente.

Información clave

Louis Laflamme

Chief Executive Officer (CEO)

CA$425.4k

Compensación total

Porcentaje del salario del CEO	76.9%
Permanencia del CEO	10.9yrs
Participación del CEO	0.6%
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	9.9yrs

Actualizaciones recientes de la dirección

Recent updates

Opsens Inc. (TSE:OPS) Just Reported And Analysts Have Been Lifting Their Price Targets

Nov 23

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Louis Laflamme en comparación con los beneficios de Opsens?
Fecha	Compensación total	Salario	Ingresos de la empresa
Aug 31 2023	n/a	n/a	-CA$12m
May 31 2023	n/a	n/a	-CA$15m
Feb 28 2023	n/a	n/a	-CA$13m
Nov 30 2022	n/a	n/a	-CA$13m
Aug 31 2022	CA$425k	CA$327k	-CA$11m
May 31 2022	n/a	n/a	-CA$9m
Feb 28 2022	n/a	n/a	-CA$6m
Nov 30 2021	n/a	n/a	-CA$4m
Aug 31 2021	CA$397k	CA$279k	-CA$1m
May 31 2021	n/a	n/a	CA$622k
Feb 28 2021	n/a	n/a	CA$1m
Nov 30 2020	n/a	n/a	-CA$179k
Aug 31 2020	CA$342k	CA$274k	-CA$3m
May 31 2020	n/a	n/a	-CA$5m
Feb 29 2020	n/a	n/a	-CA$6m
Nov 30 2019	n/a	n/a	-CA$5m
Aug 31 2019	CA$566k	CA$254k	-CA$2m
May 31 2019	n/a	n/a	-CA$2m
Feb 28 2019	n/a	n/a	-CA$2m
Nov 30 2018	n/a	n/a	-CA$3m
Aug 31 2018	CA$308k	CA$249k	-CA$5m
May 31 2018	n/a	n/a	-CA$4m
Feb 28 2018	n/a	n/a	-CA$5m
Nov 30 2017	n/a	n/a	-CA$5m
Aug 31 2017	CA$225k	CA$190k	-CA$7m

Compensación vs. Mercado: La compensación total de Louis($USD312.94K) está por debajo de la media de empresas de tamaño similar en el mercado Canadian ($USD721.11K).

Compensación vs. Ingresos: La compensación de Louis ha aumentado mientras la empresa no es rentable.

CEO

Louis Laflamme

10.9yrs

Permanencia

CA$425,365

Compensación

Mr. Louis Laflamme, C.A, C.P.A., serves as Director at Icentia Inc. He had been an Interim Chief Financial Officer of Opsens Inc. since December 09, 2022 until March 27, 2023. He has been the Chief Executi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Alan Milinazzo	Executive Chairman of the Board	4.8yrs	CA$99.20k	0.063% CA$ 210.3k
Louis Laflamme	CEO, President & Director	10.9yrs	CA$425.37k	0.59% CA$ 2.0m
Brad Davis	Chief Commercial Officer	1.8yrs	CA$756.25k	sin datos
John Hannigan	Chief Financial Officer	less than a year	sin datos	sin datos
Pierre Poulin	Corporate Controller	no data	sin datos	sin datos

3.3yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de OPS se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Alan Milinazzo	Executive Chairman of the Board	4.8yrs	CA$99.20k	0.063% CA$ 210.3k
Louis Laflamme	CEO, President & Director	10.9yrs	CA$425.37k	0.59% CA$ 2.0m
Jean Lavigueur	Independent Director	11.9yrs	CA$152.64k	0.27% CA$ 899.0k
Denis Sirois	Independent Director	17.2yrs	CA$152.94k	0.38% CA$ 1.3m
Gaetan Duplain	Director	17.2yrs	CA$294.71k	3.31% CA$ 11.1m
James Mackin	Independent Director	7.3yrs	CA$210.38k	0.038% CA$ 126.6k
Denis Harrington	Independent Director	8.9yrs	CA$90.45k	0.017% CA$ 58.0k
Lori Chmura	Independent Director	2.3yrs	CA$136.74k	sin datos

9.9yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de OPS se considera experimentada (9.9 años de antigüedad promedio).

Opsens Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Independent Director recently sold CA$79k worth of stock

Insufficient new directors

Opsens Inc., Annual General Meeting, Jan 24, 2023

Opsens Inc. Announces Departure of Robin Villeneuve as Corporate Secretary, Effective December 9, 2022

CFO & Corporate Secretary exercised options to buy CA$115k worth of stock.

CFO & Corporate Secretary exercised options and sold CA$75k worth of stock

Recent updates

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million.

New minor risk - Share price stability

Forecast to breakeven in 2025

Opsens Inc. to Report Q3, 2023 Results on Jul 13, 2023

Potential Upside For Opsens Inc. (TSE:OPS) Not Without Risk

New major risk - Financial position

OpSens Inc. Announces Inclusion of Savvywire™ in COMPLETE TAVR Study

Independent Director recently sold CA$79k worth of stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Consensus forecasts updated

No longer forecast to breakeven

First quarter 2023 earnings: Revenues exceed analyst expectations

Opsens Inc. to Report Q1, 2023 Results on Jan 12, 2023

Opsens Inc. has completed a Follow-on Equity Offering in the amount of CAD 10 million.

Price target decreased to CA$3.73

Consensus EPS estimates fall by 27%

Consensus EPS estimates fall by 21%

Full year 2022 earnings: EPS misses analyst expectations

Opsens Inc. to Report Q4, 2022 Results on Nov 22, 2022

Opsens Inc. to Report Q4, 2022 Results on Nov 22, 2022

Insufficient new directors

Opsens Inc., Annual General Meeting, Jan 24, 2023

Opsens Inc. Announces Departure of Robin Villeneuve as Corporate Secretary, Effective December 9, 2022

Opsens Inc. Announces First Savvywire Clinical Cases in Europe and Launch of Safe-Tavi Study

Opsens Announces First Savvywire Procedure in the United States by Dr. Philippe Genereux of Morristown Medical Center

OpSens Inc. Announces FDA Clearance for the SavvyWire for Use in Transcatheter Aortic Valve Replacement (TAVR) Procedures

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast breakeven date pushed back to 2024

Opsens Inc. to Report Q3, 2022 Results on Jul 14, 2022

CFO & Corporate Secretary exercised options to buy CA$115k worth of stock.

CFO & Corporate Secretary exercised options and sold CA$75k worth of stock

Opsens Inc. Announces New Data Supporting the Safety and Efficacy of its SavvyWire Recently Approved by Health Canada for Transcatheter Aortic Valve Replacement Procedures

Insufficient new directors

Opsens Inc. Announces Health Canada Approval for Its New TAVR Guidewire

Consensus EPS estimates fall by 69%

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Opsens Inc. to Report Q2, 2022 Results on Apr 13, 2022

Insufficient new directors

Insufficient new directors

OpSens Inc Appoints Brad Davis as Chief Commercial Officer

Independent Director exercised options to buy CA$245k worth of stock.

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Opsens Inc. Announces 510(K) Submission to U.S. FDA for New Guidewire for the Tavr Procedure

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to CA$4.28

Opsens Inc. Successfully Completes 20-Patient in Human Clinical Study for TAVR Procedure

Independent Director recently sold CA$139k worth of stock

Independent Director exercised options to buy CA$368k worth of stock.

President exercised options and sold CA$230k worth of stock

Director recently bought CA$310k worth of stock

Director recently bought CA$310k worth of stock

Price target increased to CA$3.79

OPSENS Receives Approval from Health Canada to Initiate First In-Man Clinical Study for its New Guidewire for the TAVR Procedure

Insufficient new directors

Independent Director recently bought CA$150k worth of stock

Independent Director recently bought CA$150k worth of stock

Consensus forecasts updated

Third quarter 2021 earnings released

Opsens (TSE:OPS) Has Debt But No Earnings; Should You Worry?

Price target increased to CA$3.00

Second quarter 2021 earnings released: EPS CA$0.001 (vs CA$0.015 loss in 2Q 2020)

Price target raised to CA$2.56

Opsens Inc. has completed a Follow-on Equity Offering in the amount of CAD 25 million.